Publication | Open Access

Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program

Breast OncologyMedicineCancer ManagementPharmacologyBreast CancerCancer TreatmentOncologyRadiation OncologyCancer ResearchEndocrine-related Cancer